Axsome Therapeutics, Inc.

AXSM Healthcare Biotechnology

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024. In the quarter to June 2026, revenue grew 45.5%, EPS fell 2.06%, free cash flow fell 2.98% and total debt rose 4.66%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

157.14 4.65 −2.87%
Market cap
$8.5B
P/E
0.0×
Fwd P/E
−121×
Dividend yield
—
F-score
5/9
Altman Z
6.91
Beneish M
−2.53
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 5 5 5

+8 more TTM periods

ROE
(245.10%) (349.38%) (252.11%) (275.50%)
ROA
(27.35%) (28.74%) (29.11%) (37.30%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(97.28%) (109.12%) (86.93%) (111.61%)
Average Days of Receivables
130.41 129.39 128.32 127.79
Free Cash Flow per Share
(1.39) (1.39) (1.89) (2.03)
Free Cash Flow
(71.96) (70.99) (93.88) (101.39)
Capital Expenditures
(0.70) (0.26) (0.48) (0.44)
Other line items
Cash ROIC
(13.57%) (14.69%) (17.61%) (19.45%)
Accounts Receivable Turnover
3.26 3.43 3.48 3.50
Accounts Payable Turnover
0.62 0.55 0.69 0.77
Inventory Turnover
1.87 2.19 2.17 2.40
Average Days of Payables
548.71 743.05 503.83 433.46
Days of Inventory on Hand
263.23 219.46 214.78 190.03
Tax Rate
0.00 0.00 (0.01) 0.00
Research and Development Expense of Revenue
24.19% 26.99% 28.70% 33.76%
Selling, General and Administrative Expense of Revenue
91.77% 89.63% 89.37% 91.68%
Share Based Compensation of Revenue
12.42% 13.26% 14.68% 16.57%
Interest Coverage
(37.09) (32.60) (25.43) (27.97)
Operating CF/Net income
0.37 0.38 0.51 0.44
Depreciation/Fixed assets
12.11 17.80 18.45 17.71
Capex/Depreciation
(0.07) (0.03) (0.05) (0.04)
Revenue per Share
14.99 13.83 12.83 11.22
Operating CF per Share
(1.38) (1.38) (1.88) (2.02)
Capex per Share
(0.01) (0.01) (0.01) (0.01)
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates